EVALUATING: Antibody Drug Conjugates

EVALUATING

ANTIBODY DRUG CONJUGATES

Big pharma are dishing out billions to buy or license them: in 2023, Pfizer paid $43 billion for Seagen, AbbVie stumped up over $10 billion for ADC pioneer ImmunoGen, and Merck forked out $4 billion up-front – and potentially up to $22 billion –...Contents

ADC Market Landscape

EVALUATING
Key Players

EVALUATING
Ones to Watch

Thank you for reading

EVALUATING:
Antibody Drug Conjugates